Correction to: FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
1 Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA. [email protected].
2 Department of Biostatistics, Colleges of Medicine, Public Health & Health Professions, University of Florida, Gainesville, FL, USA.
3 Center for Cancer and Blood Disorders, Children's Hospital Colorado, Aurora, CO, USA.
4 Texas Children's Hospital, Houston, TX, USA.
5 Department of Genetics, University of Alabama at Birmingham, Birmingham, AL, USA.
6 The Ohio State University Comprehensive Cancer Center, Columbus, OH, USA.
7 Department of Global Pediatric Medicine, St. Jude Children's Research Hospital, Memphis, TN, USA.
8 U.S. Army Medical Research and Materiel Command, Fort Detrick, MD, USA.
9 Division of Pediatric Hematology/Oncology, University of Texas Southwestern School of Medicine, Dallas, TX, USA.
10 Department of Pediatrics and Perlmutter Cancer Center, NYU Langone Health, New York, NY, USA.
11 Departments of Pathology and Oncology, Johns Hopkins University, Baltimore, MD, USA.
12 Division of Pediatric Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA.
13 Department of Pediatrics, Benioff Children's Hospital and the Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, CA, USA.
14 Department of Pediatrics and the Center for Childhood Cancer Research, Children's Hospital of Philadelphia and the Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.